Antithrombin Market Size, Share & Trends Analysis Report By Source (Human, Recombinant Goat Milk), By Dosage Form (Lyophilized Powder, Liquid Form), By Application (Therapeutics, Research, Diagnostics, Others), By End User (Hospitals, Specialty Clinics, Academic & Research Institutes, Diagnostic Laboratories, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Antithrombin Market Size & Growth Analysis

The global antithrombin market size was valued at USD 443.22 million in 2025 and is projected to grow from USD 465.16 million in 2026 to USD 684.64 million by 2034, registering a CAGR of 4.95% during the forecast period from 2026 to 2034. North America dominated the antithrombin market with a market share of 38.4% in 2025.

Market Segmentation

Source Insights

The recombinant goat milk segment is gaining prominence due to its innovative use in producing recombinant human antithrombin. This biotechnological approach involves genetically modified goats that secrete this molecule in their milk, enabling scalable and cost-effective production. Recombinant sources eliminate the risk of blood-borne pathogen transmission and offer improved consistency and purity compared to plasma-derived products. Companies like rEVO Biologics have commercialized such products, enhancing treatment accessibility for hereditary antithrombin deficiency and improving patient safety profiles globally.

Request Customizationto receive a tailored report.

Dosage Form Insights

The lyophilized powder segment is growing due to its enhanced stability and longer shelf life. This freeze-dried formulation of antithrombin allows for convenient storage and transportation, especially in regions with limited cold chain infrastructure. It is widely used in clinical settings where reconstitution before administration is feasible, such as in surgical procedures or intensive care. The segment’s reliability and ease of distribution make it a preferred choice among healthcare providers handling critical thrombosis-related interventions.

Application Insights

The therapeutics segment holds a significant share of the market, driven by its extensive use in treating hereditary antithrombin deficiency and preventing thromboembolic events. This molecule is also utilized during high-risk surgeries, such as cardiac and organ transplants, where anticoagulation is essential. Its application in managing sepsis-associated coagulopathy is also under investigation. As awareness increases and clinical guidelines evolve, the therapeutic use of antithrombin continues to expand, reinforcing its role as a critical biological agent in modern medicine.

End-User Insights

Hospitals represent the largest end-user segment in the market due to their central role in administering antithrombin for acute care settings. The product is frequently used in surgical theaters, intensive care units, and during high-risk deliveries. Hospitals are well-equipped with the infrastructure needed to handle both recombinant and plasma-derived forms of antithrombin. Additionally, increased hospital admissions related to cardiovascular disorders and thrombotic complications contribute to the rising demand, reinforcing the importance of this segment in overall market growth.

Speak to an Analystto discuss market opportunities.

Regional Insights

The North American market is expanding due to advanced healthcare infrastructure, increased adoption of recombinant biologics, and high awareness of coagulation disorders. Robust diagnostic capabilities, favorable reimbursement frameworks, and proactive screening for thrombophilia further support market penetration. Growth is also driven by ongoing clinical trials and innovation in anticoagulant therapies. The presence of major biopharmaceutical players and collaborations with research institutions enhances the development pipeline. Increased surgical procedures, especially organ transplants and cardiovascular surgeries, are boosting the clinical demand for antithrombin supplementation across hospitals and specialty clinics.

U.s. Antithrombin Market Trends

• The U.S. market is driven by high thrombotic disease prevalence and advanced healthcare infrastructure. The FDA-approved recombinant antithrombin, ATryn by rEVO Biologics, is widely used in hereditary antithrombin deficiency cases. Increased surgical procedures and a strong focus on rare disease treatments also contribute to market growth. Moreover, significant R&D investments and government incentives support continuous innovation in biologic therapies targeting coagulation disorders.
• Canada’s antithrombin market is expanding due to improved diagnostic screening and public awareness about thrombosis-related risks. The Canadian Blood Services facilitates the distribution of plasma-derived antithrombin, especially in critical care and surgical settings. Additionally, national health programs support the early detection of hereditary deficiencies. Ongoing collaboration between hospitals and biotech firms further enhances treatment access, with emphasis on cost-effective biologics in managing congenital and acquired antithrombin deficiencies.

Unlock Regional Insightsto access country-level data, & regional trends.

Asia-Pacific: Significantly Growing Region

The Asia Pacific market is rapidly evolving due to rising awareness of thrombosis-related conditions and expanding diagnostic infrastructure. Growing healthcare investments, coupled with increasing affordability of biologics, support broader market accessibility. Demand is being fueled by rising surgical volumes and greater use of anticoagulants in intensive care and transplant settings. Government initiatives promoting rare disease management and improved pharmacovigilance are also contributing factors. The increasing presence of biopharma companies in local markets is fostering technology transfer, aiding in the production and distribution of cost-effective recombinant antithrombin products.

• China’s antithrombin market is witnessing growth due to increasing awareness of thrombotic disorders and rising surgical volumes. The government's focus on rare disease diagnosis has improved accessibility to treatments like recombinant antithrombin. For example, regulatory reforms under China’s National Rare Disease Registry System are accelerating approvals. Additionally, domestic biopharma players like WuXi Biologics are entering the space, boosting local manufacturing and R&D.
• India’s market for antithrombin is expanding gradually, driven by growing cases of deep vein thrombosis and increased organ transplant procedures. Government programs like Ayushman Bharat have improved access to critical care, indirectly supporting anticoagulant use. For instance, tertiary hospitals such as AIIMS are adopting recombinant antithrombin for surgery-related coagulopathy. However, affordability remains a challenge, prompting interest in cost-effective biosimilars from Indian firms like Biocon and Intas.

Europe: Substantial Potential for Growth

Europe’s market is witnessing steady growth owing to stringent regulatory standards, strong emphasis on patient safety, and wide adoption of recombinant antithrombin therapies. The region benefits from structured healthcare systems, early disease screening protocols, and active surveillance of thrombotic disorders. High prevalence of rare bleeding disorders and a growing geriatric population enhance therapeutic demand. Research initiatives funded by the public and private sectors are accelerating innovation. Hospitals and specialized clinics increasingly prefer antithrombin in perioperative settings, especially in cardiovascular and orthopedic surgeries, reinforcing its importance in clinical anticoagulation protocols.

• Germany’s antithrombin industry benefits from a well-established healthcare system and strong pharmaceutical R&D. The country’s focus on rare disease management supports the use of antithrombin in hereditary deficiency cases. For instance, clinics affiliated with Charité – Universitätsmedizin Berlin are actively involved in clinical trials using recombinant antithrombin. Additionally, Germany’s emphasis on advanced surgical procedures drives demand for antithrombin during transplant and cardiac surgeries.
• The UK antithrombin market is driven by NHS initiatives to improve the diagnosis and treatment of thrombotic conditions. Growing awareness around hereditary thrombophilia has led to increased screening and therapeutic use of antithrombin. For example, the Royal Free London NHS Trust has adopted recombinant antithrombin in critical care settings. The UK’s support for orphan drugs and robust clinical research ecosystem also accelerates antithrombin adoption and innovation.

Company Market Share

Companies in the market for antithrombin are focusing on expanding their market share through strategic initiatives such as increasing investment in R&D, developing recombinant antithrombin therapies, and enhancing production capabilities. They are also pursuing regulatory approvals in emerging markets, forming partnerships with hospitals and research institutions, and expanding their presence in high-growth regions. Additionally, many are emphasizing awareness campaigns and early diagnostics to drive demand and boost long-term adoption of antithrombin treatments.

Grifols S.A.: Grifols S.A., headquartered in Barcelona, Spain, is a global healthcare company specializing in plasma-derived therapies. A key player in the antithrombin market, Grifols develops and manufactures biologic medicines to treat rare and chronic conditions, including antithrombin deficiency. With a strong portfolio of plasma-derived products, the company emphasizes innovation, research, and global plasma collection infrastructure. Grifols’ focus on quality and safety standards has positioned it as a trusted provider of antithrombin therapies across hospitals, surgical units, and critical care settings.

• In July 2025, Grifols announced a €160 million investment to build a new plasma fractionation plant in Lliçà de Vall (Barcelona), doubling its European processing capacity. Scheduled to be operational by 2030, the 80,000 m² facility will bolster supply of antithrombin and other plasma-derived therapies, create over 400 jobs, and integrate renewable energy systems.

List of Key and Emerging Players in Antithrombin Market